Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 21, 2026, 11:39 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–16 of 16 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Proteinuric Renal Disease Clear all
Terminated Phase 4 Interventional
View directory record Official record
Conditions
Microalbuminuria, Macroalbuminuric Diabetic Nephropathy, Diabetes, Proteinuria, Albuminuria
Interventions
Aliskiren
Drug
Lead sponsor
Cook County Health
Government
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 27, 2013 · Synced May 21, 2026, 11:39 PM EDT
Not listed Not applicable Interventional
View directory record Official record
Conditions
Diabetic Nephropathy
Interventions
Minocycline 100 mg po bid for 6 months, placebo
Drug
Lead sponsor
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated May 20, 2015 · Synced May 21, 2026, 11:39 PM EDT
Withdrawn Not applicable Interventional
View directory record Official record
Conditions
Proteinuric Renal Disease
Interventions
paricalcitol (initial dose 1 mcg orally per day)
Drug
Lead sponsor
Winthrop University Hospital
Other
Eligibility
18 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Mineola, New York
Source: ClinicalTrials.gov public record
Updated Dec 27, 2015 · Synced May 21, 2026, 11:39 PM EDT
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
Proteinuric Kidney Diseases
Interventions
BI 764198, Placebo matching BI 764198
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
12 Years and older
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
25
States / cities
Huntsville, Alabama • Glendale, California • Granada Hills, California + 21 more
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced May 21, 2026, 11:39 PM EDT
Not yet recruiting Phase 1 Interventional
View directory record Official record
Conditions
Proteinuric Renal Disease, Proteinuric Kidney Disease, Proteinuria, Proteinuria in Nephrotic Range
Interventions
sparsentan, No sparsentan
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 17, 2026 · Synced May 21, 2026, 11:39 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Proteinuria
Interventions
Belatacept
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 8, 2022 · Synced May 21, 2026, 11:39 PM EDT
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
Focal Segmental Glomerulosclerosis, Minimal Change Disease, Immunoglobulin A Nephropathy, IgA Vasculitis, Alport Syndrome
Interventions
Sparsentan
Drug
Lead sponsor
Travere Therapeutics, Inc.
Industry
Eligibility
1 Year to 17 Years
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
23
States / cities
Los Angeles, California • Wilmington, Delaware • Miami, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced May 21, 2026, 11:39 PM EDT
Active, not recruiting Phase 2 Interventional
View directory record Official record
Conditions
IgA Nephropathy, Focal Segmental Glomerulosclerosis, Alport Syndrome, Diabetic Kidney Disease, Diabetic Nephropathy Type 2, Immunoglobulin A Nephropathy
Interventions
Atrasentan
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
14
States / cities
Glendale, California • Los Angeles, California • San Dimas, California + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2025 · Synced May 21, 2026, 11:39 PM EDT
Not listed Phase 4 Interventional
View directory record Official record
Conditions
Proteinuria
Interventions
Amiloride, Triamterene
Drug
Lead sponsor
Georgetown University
Other
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Feb 6, 2020 · Synced May 21, 2026, 11:39 PM EDT
Terminated Phase 4 Interventional Results available
View directory record Official record
Conditions
Proteinuric Kidney Disease, Diabetic Nephropathy, Hypertensive Nephrosclerosis, IgA Nephropathy, Focal Segmental Glomerulosclerosis, Glomerulopathy (Obesity-associated), Glomerulonephritis, Membranous
Interventions
Aliskiren, Valsartan
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 14, 2014 · Synced May 21, 2026, 11:39 PM EDT
Active, not recruiting Phase 2 Interventional
View directory record Official record
Conditions
Proteinuric Kidney Disease
Interventions
Inaxaplin
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 67 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
35
States / cities
Huntsville, Alabama • Hollywood, Florida • Lauderdale Lakes, Florida + 28 more
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced May 21, 2026, 11:39 PM EDT
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
Proteinuric Kidney Disease
Interventions
MZE829
Drug
Lead sponsor
Maze Therapeutics
Industry
Eligibility
18 Years to 68 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
72
States / cities
Decatur, Alabama • Huntsville, Alabama • Montgomery, Alabama + 60 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced May 21, 2026, 11:39 PM EDT
Completed No phase listed Observational
View directory record Official record
Conditions
Fabry Disease, Proteinuria
Interventions
enalapril and other angiotensin converting enzyme inhibitors; losartan and other angiotensin receptor blockers
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years to 85 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
5
States / cities
Birmingham, Alabama • Atlanta, Georgia • Chicago, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2013 · Synced May 21, 2026, 11:39 PM EDT
Recruiting Phase 2Phase 3 Interventional
View directory record Official record
Conditions
Proteinuric Kidney Disease
Interventions
VX-147, Placebo
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
10 Years to 65 Years
Enrollment
466 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
227
States / cities
Alabaster, Alabama • Birmingham, Alabama • Fairhope, Alabama + 145 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced May 21, 2026, 11:39 PM EDT
Terminated Phase 2 Interventional Results available
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
AZD5718, Dapagliflozin 10 mg, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
613 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
22
States / cities
Canoga Park, California • La Mesa, California • San Carlos, California + 19 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2024 · Synced May 21, 2026, 11:39 PM EDT
Recruiting Phase 3 Interventional
View directory record Official record
Conditions
Hypertension (HTN)
Interventions
Combination Product: FDC of spironolactone and ER torsemide, Combination Product: Stabilized doses of loop diuretic and finerenone
Drug
Lead sponsor
Sarfez Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Vienna, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 8, 2026 · Synced May 21, 2026, 11:39 PM EDT